Effect of Cost and Formulation on Persistence and Adherence to Initial Metformin Therapy for Type 2 Diabetes
- PMID: 32253222
- PMCID: PMC7245354
- DOI: 10.2337/dc19-2426
Effect of Cost and Formulation on Persistence and Adherence to Initial Metformin Therapy for Type 2 Diabetes
Similar articles
-
Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin.Patient Prefer Adherence. 2016 Aug 10;10:1539-46. doi: 10.2147/PPA.S109664. eCollection 2016. Patient Prefer Adherence. 2016. PMID: 27570448 Free PMC article.
-
[One year persistence of metformin monotherapy versus metformin/sitagliptin fixed dose combination].Orv Hetil. 2016 Apr 17;157(16):618-22. doi: 10.1556/650.2016.30423. Orv Hetil. 2016. PMID: 27063429 Hungarian.
-
Advantages of extended-release metformin in patients with type 2 diabetes mellitus.Postgrad Med. 2011 Jan;123(1):15-23. doi: 10.3810/pgm.2011.01.2241. Postgrad Med. 2011. PMID: 21293080 Review.
-
Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy.Am J Ther. 2014 May-Jun;21(3):198-210. doi: 10.1097/MJT.0b013e318235f1bb. Am J Ther. 2014. PMID: 22314210 Review.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
-
Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study.Eur Heart J. 2021 Oct 21;42(40):4126-4137. doi: 10.1093/eurheartj/ehab421. Eur Heart J. 2021. PMID: 34269375 Free PMC article.
-
Adherence and persistence rates of major antidiabetic medications: a review.Diabetol Metab Syndr. 2022 Jan 15;14(1):12. doi: 10.1186/s13098-022-00785-1. Diabetol Metab Syndr. 2022. PMID: 35033161 Free PMC article. Review.
References
-
- Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab 2009;11:338–342 - PubMed
-
- Newman D, Herrera CN, Parente ST. Overcoming barriers to a research-ready national commercial claims database. Am J Manag Care 2014;20:eSP25–30 - PubMed